Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots

Ali Judd*, John Parry, Matthew Hickman, Tamara McDonald, Laura Jordan, Kim Lewis, Marcela Contreras, Geoff Dusheiko, Graham Foster, Noël Gill, Katie Kemp, Janice Main, Iain Murray-Lyon, Mark Nelson

*Corresponding author for this work

Research output: Contribution to journalArticle (Academic Journal)peer-review

145 Citations (Scopus)


Oral fluid testing is an effective alternative to serum antibody testing for surveillance of human immunodeficiency virus (HIV) and hepatitis B infections, and is being extended to hepatitis C infections. The objective of this study was to determine and compare the sensitivity and specificity of a modified commercial assay for the detection of antibody to hepatitis C virus (anti-HCV) in oral fluids collected by two different oral fluid collection devices (the Epitope OraSure™ and Sarstedt Salivette™) and in dried fingerprick blood spots. In this study, 253 anti-HCV seropositive patients and 394 blood donors (all anti-HCV negative) were recruited between August 2000 and January 2001. Each participant provided oral fluid specimens by OraSure and Salivette, and at least one dried blood spot. Serum specimens were collected from the patients whenever possible. For those injecting drug users who did not provide a serum specimen, HCV status was established on the basis of previous testing. All the nonserum samples were tested for the presence of anti-HCV, using a modified Ortho HCV 3.0 SAVe enzyme-linked immunosorbent assay (ELISA) protocol. The recommended preliminary cutoffs for the modified ELISA were suboptimal. Further, the sensitivity, specificity, and positive and negative predictive values could be improved by varying the cutoff and taking into account the likely prevalence of HCV in the population under investigation. For instance, given a population with a 50% prevalence of anti-HCV, the optimal sensitivities of the modified assay on OraSure, Salivette, and dried blood spots were 92%, 83%, and virtually 100%, respectively, in contrast to 83%, 59%, and 99% using the preliminary cutoffs. The respective optimal specificities were 99%, 93%, and 100%. In conclusion, oral fluids collected by the OraSure device provide an extremely useful method to conduct public health surveillance of not only HIV, but also hepatitis C, among injecting drug users. In addition, dried blood spot specimens may be useful for surveillance and could be employed as a first line diagnostic specimen.

Original languageEnglish
Pages (from-to)49-55
Number of pages7
JournalJournal of Medical Virology
Issue number1
Publication statusPublished - 1 Sept 2003


  • Antibody
  • Assay
  • Dried blood spots
  • HCV
  • Hepatitis C
  • Oral fluid


Dive into the research topics of 'Evaluation of a modified commercial assay in detecting antibody to hepatitis C virus in oral fluids and dried blood spots'. Together they form a unique fingerprint.

Cite this